| Congresso Brasileiro de Microbiologia 2023 | Resumo: 512-2 | ||||
Resumo:In many individuals with compromised immune function due to cancer or COVID-19, Candida species can invade the bloodstream and cause disseminated candidiasis. Patients infected with COVID-19 present a severe acute respiratory syndrome as its main symptom, which is an aggravating risk of acquiring infections by Candida sp. that cause oral candidiasis and invasive fungal infections. Oral candidiasis also often appears in patients with cancer irradiated in the head and neck region during antineoplastic treatment and makes food intake difficult. In this phase, patients experience a transient immunosuppression, in which there is proliferation of opportunistic fungi such as Candida sp. Candida albicans is the yeast that most commonly causes oral candidiasis, it can also invade the bloodstream and cause disseminated candidiasis. But other yeasts like C. parapsilosis, C. tropicalis and C. glabrata can also cause severe fungal infections in immunosuppressed patients. The therapeutic arsenal for the treatment of candidiasis is limited and expensive, and includes classes of antifungal drugs such as polyenes, azoles and echinocandins, which can cause fungal resistance and nephrotoxicity. The imidazolium salts (IS) have already proven biological activities, such as antimicrobial, antitumor, among others. And they are versatile compounds, which have chemical structures that allow structural changes in both the cation and the anion. Therefore, the objective of this study is to evaluate the effectiveness of a N-benzyl-substituted IS against different Candida sp., which could serve as active pharmaceutical ingredient in the development of formulations for the treatment of oral and systemic candidiasis. The activity of this compound was compared with that of miconazole, a commercial antifungal widely used in the treatment of candidiasis. The IS used was synthesized according to a literature procedure. The minimum inhibitory concentration (MIC) assay was performed according to international standard protocols CLSI M27-A2 and CLSI M38-A. The MIC of the N-benzyl-substituted IS was determined using the serial broth dilution method. The assays were performed in duplicate and the results were verified after 24 and 48 h. Ten yeast strains (C. tropicalis ATCC13803, C. Krusei ATCC34135, C. glabrata ATCC2001, C. albicans ATCC44858, C. albicans CFP00107, C. tropicalis CPF00319, C. parapsilosis CFP00893, C. albicans CFP00895, C. albicans CPF00283, C. albicans CFP00292) that are part of the mycology collection of the Multidisciplinary Group in Medical and Microbiological Chemistry were selected. For all ten yeast isolates tested, the MIC for the N-benzyl-substituted IS was 1 μg/mL. MIC were obtained with miconazole for C. tropicalis ATCC13803, C. albicans ATCC44858, C. albicans CFP00107, C. tropicalis CPF00319, C. parapsilosis CFP00893, C. albicans CPF00283 and C. albicans CFP00292 of 4 μg/mL, for C. Krusei ATCC34135 of 32 μg/mL, for C. glabrata ATCC2001 of 8 μg/mL and for C. albicans CFP00895 of 2 μg/mL. As a consequence, the N-benzyl- substituted IS showed high efficacy to inhibit the growth of Candida sp., presenting lower MIC when compared to miconazole. Being a promising compound for the development of antifungal formulations as strategy for the treatment of oral and systemic candidiasis.
Palavras-chave: Imidazolium ionic liquid, Antifungal, Antimicrobial, Minimum inhibitory concentration, Miconazole Agência de fomento:Coordination for the Improvement of Higher Education Personnel – Brazil (CAPES) – Finance Code 001. | |||||